Tacrolimus

• Preparation for bone marrow transplantation through the combined use of chemo and radiotherapy (Reduced intensity: with lower doses or diffe… Recruiting
  2024-514483-11-00 Phase II 1 country Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevil…
• Preparation for bone marrow transplant through the combined use of chemo and radiotherapy (intensive or myeloablative: eliminates stem cells… Recruiting
  2024-514484-25-00 Phase II 1 country Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevil…
• A clinical trial to learn about the effects of YTB in people with difficult to treat active systemic lupus erythematosus (SLE), or active k… Recruiting
  2023-510150-17-00 Phase II 13 countries Novartis Pharma AG
• Prospective, multicenter, randomized, open-label, parallel-group controlled phase 3 study of tacrolimus minimization in kidney transplant re… Recruiting
  2022-502624-44-00 Phase III 3 countries Centre Hospitalier Universitaire De Nantes
• A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Generalized Myasthenia Gravis Recruiting
  2023-509892-17-00 Phase II/III 1 country Kyverna Therapeutics Inc.
• A clinical trial applying Regulatory T cells in kidney transplant recipients to investigate the safety and tolerability as an adjunctive the… Recruiting
  2024-514398-23-00 Phase I/II 1 country Charite Universitaetsmedizin Berlin KöR
• Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects Recruiting
  2023-510486-10-00 Phase IV 1 country Oslo University Hospital HF
• A multi-centre, open, prospective, randomized, parallel-group, 24-month study to compare the outcome of receiving continued immunosuppressio… Recruiting
  2023-506879-98-00 Phase IV 1 country Vall D'hebron Institut De Recerca
• A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat… Recruiting
  2022-502851-79-00 Phase III 19 countries Argenx
• Trial evaluating the safety and efficacy of Venetoclax in addition to a standard conditioning regime in patients with certain forms of leuke… Recruiting
  2024-514688-24-00 Phase I/II 1 country Heinrich-Heine-Universitaet Duesseldorf
• Cyclophosphamide and Azathioprine vs Tacrolimus in antisynthetase syndrome-related interstitial lung disease: multicentric randomized phase … Recruiting
  2024-511868-83-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• Clinical trial to evaluate effectiveness and cost-effectiveness of pre-emptive genotyping strategy to optimise tacrolimus dosage in a pretra… Ended
  2024-516596-32-00 Phase IV 1 country Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz
• BESTOW-EXTENSION: A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long- Term Safety and Efficacy of Tegoprubart in Kidney… Ended
  2023-503337-21-00 Phase II 3 countries Eledon Pharmaceuticals Inc.
• A clinical trial to learn about the effects of YTB323 in people with difficult-to-treat severe inflammatory myopathies (IIM) Ended
  2024-514137-38-00 Phase II 5 countries Novartis Pharma AG
• A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab compared with treatment withdrawal in… Ended
  2023-508096-36-00 Phase III 11 countries Sanofi-Aventis Recherche & Developpement
• Topical tacrolimus for the amelioration of breast cancer-related lymphedema: a randomized, double-blind, placebo-controlled phase II/III tri… Ended
  2023-503644-13-00 Phase III 1 country Odense University Hospital
• Multicentre, open-label, randomised, two-arm, parallel-group, superiority trial to assess bioavailability and practicability of two once-dai… Ended
  2023-503531-18-00 Phase IV 1 country Universitaetsklinikum Regensburg
• Efficacy and Safety of Methotrexate versus Placebo in Adults with Atopic Dermatitis Ended
  2023-504443-13-00 Phase III 4 countries Medac Gesellschaft fuer klinische Spezialprapaerate mbH
• A Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropathy Ended
  2023-506525-11-00 Phase III 4 countries F. Hoffmann-La Roche AG
• A clinical trial evaluating the efficacy and safety of the drugs - cyclosporine and methotrexate in children and adolescents with moderate t… Ended
  2023-509759-15-00 Phase III 1 country Medical University Of Lodz
• Multicentre, open-label, randomised, two-arm, parallel-group, superiority study to assess bioavailability and practicability of Envarsus® co… Ended
  2024-518033-28-00 Phase IV 1 country Universitaetsklinikum Regensburg AöR
• Evaluation of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Patients with Moderate to Severe Atopic Derma… Ended
  2022-502937-24-00 Phase III 18 countries Abbvie Deutschland GmbH & Co. KG
• Immunosuppressive drug bioequivalence in kidney transplant recipients – Prograf and CellCept Ended
  2025-521800-22-00 Phase IV 1 country Oslo University Hospital HF
• CALCIGRAN FORTE AND DOSING OF IMMUNOSUPPRESSIVE DRUGS IN KIDNEY TRANSPLANT RECIPIENTS Ended
  2024-515164-30-00 Phase IV 1 country Oslo University Hospital HF

Showing 25–48 of 61 trials